Volume 10,Issue 4
AI-assisted Precision Diagnosis and Treatment of Liver Disease: Current Status and Future
Artificial intelligence (AI) technology is driving the rapid development of precision medicine, providing new tools and ideas for early diagnosis, risk prediction, and individualized treatment of liver diseases. This paper summarizes the latest research progress of AI in precision diagnosis and treatment of liver diseases, focusing on the major diseases such as hepatocellular carcinoma, non-alcoholic fatty liver disease and drug-induced liver injury. It first summarizes the current traditional methods of imaging, laboratory testing and pathology diagnosis and their limitations; and then focuses on the value of deep learning image analysis, machine learning models based on electronic medical records, and multi-omics data integration in improving diagnostic accuracy and evaluating disease progression. The article further analyzes the strengths and weaknesses of AI applications, including the lack of data standardization, insufficient model interpretability, limited cross-center generalization capabilities, and ethical and privacy challenges. Finally, it looks at future directions in terms of multimodal fusion, interpretable AI and individualized closed-loop management. The aim of this paper is to provide a systematic reference for research and clinical application of precision diagnosis and treatment of liver diseases.
[1] Galle P, Forner A, Llovet J, et al., 2018, EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69(1): 182–236.
[2] Huang D, El-Serag H, Loomba R, 2021, Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 18(4): 223–238.
[3] Niu H, Alvarez-Alvarez I, Chen M, 2025, Artificial Intelligence: An Emerging Tool for Studying Drug-Induced Liver Injury. Liver International, 45(3): e70038.
[4] Williams R, 2006, Global Challenges in Liver Disease. Hepatology, 44(3): 521–526.
[5] Balogh J, Victor D, Asham E, et al., 2016, Hepatocellular Carcinoma: A Review. Journal of Hepatocellular Carcinoma, 41–53.
[6] Stephens C, Andrade R, 2020, Genetic Predisposition to Drug-Induced Liver Injury. Clinics in Liver Disease, 24(1): 11–23.
[7] Topol E, 2019, High-Performance Medicine: The Convergence of Human and Artificial Intelligence. Nature Medicine, 25(1): 44–56.
[8] Azer S, 2019, Deep Learning with Convolutional Neural Networks for Identification of Liver Masses and Hepatocellular Carcinoma: A Systematic Review. World Journal of Gastrointestinal Oncology, 11(12): 1218.
[9] Lin B, Ma Y, Wu S, 2022, Multi-Omics and Artificial Intelligence-Guided Data Integration in Chronic Liver Disease: Prospects and Challenges for Precision Medicine. OMICS: A Journal of Integrative Biology, 26(8): 415–421.